PHOSPHAGENICS GETS APPROVAL FOR TRIAL OF TRANSDERMAL INSULIN DELIVERY

Phosphagenics has received approval to begin Phase I clinical trials of its transdermal insulin delivery product TPM-02/Insulin.

The product is being developed as a novel way of administering insulin to diabetics, and this trial -- which is planned to begin this month -- follows on from the successful preclinical trials that were reported on in May 2006.

In the proposed study, 20 healthy male volunteers will be randomly assigned to receive either TPM-02/Insulin or a placebo, applied in a single dose directly to the skin.